US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

UK contract research organization hVIVO (AIM: HVO) is gearing up to test an inhaled antiviral candidate, IN-002, for ...

Inhalon Biopharma, Inc. (Inhalon), a clinical-stage company advancing a first-in-class inhaled antibody platform for treating acute respiratory infections (ARI), today announced the completion of ...

(Alliance News) - hVIVO PLC on Monday said it has signed a contract with Inhalon Biopharma Inc to test its antiviral candidate to treat respiratory syncytial virus. The London-based contract research ...

Confronting a bird flu outbreak in nature presents unique challenges, as infected animals leave a landscape contaminated, Pa.

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.

What you need to know ### BMJ Learning To obtain accredited continuous professional development points, subscribers to BMJ Learning can complete the full module at The module contains seven ...

K92 Mining Inc. ("K92" or the "Company") announces that it will release its 2024 fourth quarter financial results before the North American trading markets open on Monday, March 17, 2025. Conference ...

To accommodate an influx of patients suffering from respiratory illnesses, Union Health has installed a portable medical tent ...

It’s that time of year where everyone seems like they’re dealing with some kind of bug in their household. The holidays are ...